Pricing Log in Create free account
Tuesday 13 October 2026 Export ASMB’s income statement to Excel — free account

Assembly Biosciences, Inc.

ASMB Healthcare Biotechnology

Assembly Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $72.3 million, up 153.5% from fiscal 2024. In the quarter to June 2026, revenue grew 38.9%, EPS grew 85.0% and free cash flow grew 7.58%, each against the same quarter a year earlier. Revenue growth for three consecutive years.

20.65 2.12 −9.31%
Market cap
$463.6M
P/E
22.3×
Fwd P/E
−21.1×
Dividend yield
—
F-score
4/9
Altman Z
1.06
Beneish M
n/a
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Assembly Biosciences, Inc. (ASMB) Business Profile

Updated before January 2025

Company Overview

Assembly Biosciences, Inc. (ASMB) is a clinical-stage biotechnology company dedicated to the discovery and development of innovative therapeutics for the treatment of viral diseases. Founded in 2012 and headquartered in South San Francisco, California, ASMB has established itself as a leader in the field of virology, with a particular focus on hepatitis B virus (HBV) and other viral infections. The company was co-founded by Derek Small, who served as its first CEO, and has since attracted a team of experienced leaders in biotechnology and pharmaceutical development. Current key leadership includes John McHutchison, MD, who serves as the Chief Executive Officer and President, and Nicole White, the Chief Financial Officer. The company’s leadership team brings decades of experience in drug development, clinical research, and corporate strategy, positioning ASMB as a strong contender in the biotechnology sector.

Core Business Segments

Assembly Biosciences focuses on the development of antiviral therapeutics, with its primary emphasis on HBV and other viral diseases. The company’s core business segments include:

1. HBV Cure Programs

ASMB’s lead programs are centered around the development of small molecule therapeutics aimed at curing chronic hepatitis B infections. These include:

  • Core Inhibitors: Designed to disrupt the HBV lifecycle by targeting the viral core protein, a critical component of HBV replication. Key candidates in this category include ABI-H3733 and ABI-H2158, which are currently in clinical trials.
  • Next-Generation Core Inhibitors: ASMB is also advancing next-generation core inhibitors with improved potency and pharmacokinetic profiles.

2. Research and Development (R&D) Programs

ASMB invests heavily in R&D to expand its pipeline of antiviral therapies. The company is exploring treatments for other viral infections, including:

  • Herpesviruses: Early-stage research into therapies targeting herpes simplex virus (HSV) and cytomegalovirus (CMV).
  • SARS-CoV-2: Investigating potential treatments for COVID-19 and other coronaviruses.

3. Collaborations and Partnerships

ASMB collaborates with academic institutions, research organizations, and pharmaceutical companies to accelerate the development of its antiviral therapies. These partnerships enable the company to leverage external expertise and resources while focusing on its core competencies.

Business Model

Assembly Biosciences operates as a clinical-stage biotechnology company, meaning its primary focus is on research and development rather than commercial product sales. The company generates revenue through:

  • Collaborative Agreements: Licensing its technologies and partnering with other pharmaceutical companies for co-development and commercialization.
  • Grants and Funding: Securing funding from government agencies and non-profit organizations to support its research initiatives.
  • Future Product Sales: While ASMB does not currently have any marketed products, it aims to generate revenue through the commercialization of its pipeline candidates upon regulatory approval.

ASMB’s business model emphasizes innovation and collaboration, with a long-term goal of bringing transformative therapies to market.

Strategic Direction

Assembly Biosciences is committed to advancing its pipeline of antiviral therapies and achieving its mission of curing chronic viral infections. Key elements of the company’s strategic direction include:

  • Pipeline Expansion: ASMB is actively exploring new therapeutic targets and expanding its research into other viral diseases beyond HBV.
  • Regulatory Milestones: The company is focused on advancing its lead candidates through clinical trials and obtaining regulatory approvals.
  • Sustainability Goals: While not a primary focus, ASMB is committed to conducting its operations in an environmentally and socially responsible manner.
  • Global Reach: ASMB aims to address unmet medical needs worldwide by developing therapies that are accessible to patients in both developed and developing markets.

Competitive Landscape

Assembly Biosciences operates in a highly competitive biotechnology sector, with several companies pursuing similar goals in antiviral therapeutics. Key competitors include:

  • Gilead Sciences: A leader in antiviral therapies, particularly for HBV and HIV.
  • Arrowhead Pharmaceuticals: Focused on RNA interference (RNAi) therapies for HBV and other diseases.
  • Vir Biotechnology: Specializes in infectious disease treatments, including HBV and COVID-19.
  • Aligos Therapeutics: Develops small molecule and oligonucleotide-based therapies for HBV and other viral infections.

ASMB differentiates itself through its proprietary core inhibitor technology and its focus on developing curative therapies for HBV.

Risk Factors

Like any clinical-stage biotechnology company, Assembly Biosciences faces several risks, including:

  • Regulatory Risks: Delays or failures in obtaining regulatory approvals for its pipeline candidates.
  • Market Dependence: Heavy reliance on the success of its HBV programs, which could impact the company’s financial stability if unsuccessful.
  • Supply Chain Disruptions: Potential challenges in sourcing raw materials and manufacturing clinical trial supplies.
  • Competition: Intense competition from larger, more established companies with greater resources.
  • Financial Risks: Dependence on external funding and the potential for dilution of shareholder value through equity financing.

Recent Developments

Assembly Biosciences has made significant progress in advancing its pipeline and corporate strategy. Recent highlights include:

  • Clinical Trial Updates: Positive interim results from Phase 2 trials of ABI-H3733 and ABI-H2158, demonstrating promising efficacy and safety profiles.
  • New Collaborations: Partnerships with leading academic institutions to explore novel antiviral targets.
  • COVID-19 Research: Initiatives to investigate potential treatments for SARS-CoV-2 and other coronaviruses.
  • Corporate Restructuring: Streamlining operations to focus resources on high-priority programs.

Investment Considerations

Investors considering Assembly Biosciences should weigh the following factors:

Strengths:

  • Innovative Pipeline: A robust pipeline of antiviral therapies with significant market potential.
  • Experienced Leadership: A seasoned management team with a track record of success in drug development.
  • Collaborative Approach: Strategic partnerships that enhance the company’s capabilities and reduce risk.

Risks:

  • Clinical and Regulatory Uncertainty: The inherent risks associated with drug development and approval.
  • Financial Dependence: Reliance on external funding to support operations and R&D activities.
  • Market Competition: Intense competition from established players in the antiviral space.

Conclusion

Assembly Biosciences, Inc. is a pioneering biotechnology company with a strong focus on developing curative therapies for chronic viral infections. While the company faces significant risks as a clinical-stage enterprise, its innovative pipeline, experienced leadership, and collaborative approach position it for long-term success. With continued progress in its HBV programs and potential expansion into other viral diseases, ASMB is well-positioned to address unmet medical needs and deliver value to patients and investors alike.